MedTrace Logo

Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.

NCT05162898 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-01-27

No results posted yet for this study

Summary

This study is a multi-center, prospective, single-arm, open-design phase II clinical study, mainly to explore the clinical effectiveness and safety of radiofrequency ablation combined with anti-PD-1 antibody toripalimab and lenvatinib in patients with short-term recurrence of hepatocellular carcinoma.

Conditions

  • Recurrent Hepatocellular Cancer

Interventions

DRUG

toripalimab

240mg,ivgtt, every three weeks as a cycle, the first day of each cycle.

DRUG

Lenvatinib

12mg (weight ≥60kg) or 8mg (weight \<60kg) orally, once a day

DEVICE

Radiofrequency ablation

ultrasound-guided percutaneous radiofrequency ablation of recurrent hepatocellular carcinoma

Sponsors & Collaborators

  • Henan Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2023-12-31
Completion
2025-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05162898 on ClinicalTrials.gov